Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFNγ-treated autologous melanoma cell vaccine recipients

Journal of Immunotoxicology

Volumn 9, Issue 3, 2012, Pages 282-291

  Ravindranath, Mepur H ^a   Selvan, Senthamil R ^b   Terasaki, Paul I ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autologous vaccine; HLA E; HLA Ia; Melanoma; Post immune; Pre immune; Shared peptides

Indexed keywords

ANTIBODY; GAMMA INTERFERON; HLA E ANTIGEN; IMMUNOGLOBULIN G; MELANOMA VACCINE;

ALLELE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL;

AUTOANTIBODIES; CANCER VACCINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; MALE; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; TIME FACTORS;

EID: 84865337813     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2011.645582     Document Type: Article

References (47)

1. Algarra, I., García-Lora, A., Cabrera, T., Ruiz-Cabello, F., and Garrido, F. 2004. Te selection of tumor variants with altered expression of classical and non-classical MHC Class I molecules: Implications for tumor immune escape. Cancer Immunol. Immunother. 53:904-910. (Pubitemid 39312657)
2. Allard, M., Oger, R., Vignard, V., Percier, J. M., Fregni, G., Périer, A., Caignard, A., Charreau, B., Bernardeau, K., Khammari, A., Dréno, B., and Gervois N. 2011. Serum soluble HLA-E in melanoma: A new potential immune-related marker in cancer. PLoS ONE 6:e21118.
3. Ametani, A., Apple, R., Bhardwaj, V., Gammon, G., Miller, A., and Sercarz, E. 1989. Examining the crypticity of antigenic determinants. Cold Spring Harbor Symp. Quant. Biol. 54:505-511. (Pubitemid 20177621)
4. Barrett, D. M., Gustafson, K. S., Wang, J., Wang, S. Z., and Ginder, G. D. 2004. A GATA factor mediates cell type-restricted induction of HLA-E gene transcription by γ-interferon. Mol. Cell Biol. 24:6194-6204. (Pubitemid 38891122)
5. Berezhnoi, A. E., Chernisheva, A. D., Zakeeva, I. R., Danilova, A. B., Danilov, A. O., Moiseenko, V. M., Geraghty, D., Gnuchev, N. V., Georgiev, G. P., Kibardin, A. V., and Larin, S. S. 2009. HLA-E molecule induction on the surface of tumor cells protects them from cytotoxic lymphocytes. Vopr. Onkol. 55:224-229.
6. Bjorkman, P. J., and Parham, P. 1990. Structure, function, and diversity of Class I major histocompatibility complex molecules. Ann. Rev. Biochem. 59:253-288.
7. Braud, V., Jones, E. Y., and McMichael, A. 1997. Te human major histocompatibility complex Class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27:1164-1169. (Pubitemid 27197219)
8. Braud, V. M., Allan, D. S., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., Lanier, L. L., and McMichael, A. J. 1998. HLA-E binds to natural killer receptors CD94/NKG2A, B and C. Nature, 391:795-799. (Pubitemid 28099678)
9. Cerboni, C., Mousavi-Jazi, M., Wakiguchi, H., Carbone, E., Kärre, K., and Söderström, K. 2001. Synergistic efect of IFNγ and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur. J. Immunol. 31:2926-2935. (Pubitemid 32994544)
10. Coupel, S., Moreau, A., Hamidou, M., Horejsi, V., Soulillou, J. P., and Charreau, B. 2007. Expression and release of sHLA-E is an immunoregulatory feature of EC activation. Blood 109:2806-2814. (Pubitemid 46482075)
11. de Kruijf, E. M., Sajet, A., van Nes, J. G., Natanov, R., Putter, H., Smit, V. T., Liefers, G. J., van den Elsen, P. J., van de Velde, C. J., and Kuppen, P. J. 2010. HLA-E and HLA-G expression in classical HLA Class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J. Immunol. 185:7452-7459.
12. Derré, L., Corvaisier, M., Charreau, B., Moreau, A., Godefroy, E., Moreau-Aubry, A., Jotereau, F., and Gervois, N. 2006. Expression and release of HLA-E by melanoma cells and melanocytes: Potential impact on the response of cytotoxic efector cells. J. Immunol. 177:3100-3107. (Pubitemid 44277827)
13. El-Awar, N. R., Terasaki, P., Anh, N., Sasaki, N., Morales-Buenrostro, L. E., Saji, H., Maruya, E., and Poli, F. 2009. Epitopes of human leukocyte antigen Class I antibodies found in sera of normal healthy males and cord blood. Human Immunol. 70:844-853.
14. + NK cells. J. Immunol. 187:3546-3554.
15. Ferrone, S., and Marincola, F. M. 1995. Loss of HLA Class I antigens by melanoma cells: Molecular mechanisms, functional signifcance and clinical relevance. Immunol. Today 16:487-494.
16. + T-lymphocytes. Proc. Natl. Acad. Sci. USA 108:10656-10661.
17. Gonçalves, M. A., Le Discorde, M., Simões, R. T., Rabreau, M., Soares, E. G., Donadi, E. A., and Carosella, E. D. 2008. Classical and non-classical HLA molecules and p16(INK4a) expression in precursors lesions and invasive cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 141:70-74.
18. Grimsley, C., Kawasaki, A., Gassner, C., Sageshima, N., Nose, Y., Hatake, K., Geraghty, D. E., and Ishitani, A. 2002. Defnitive high resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele data. Tissue Antigens 60:206-212. (Pubitemid 35398823)
19. Gustafson, K. S., and Ginder, G. D. 1996. Interferon-γ induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1α to a distinct interferon-γ-responsive element. J. Biol. Chem. 271:20035-20046.
20. Hanak, L., Slaby, O., Lauerova, L., Kren, L., Nenutil, R., and Michalek, J. 2009. Expression pattern of HLA Class I antigens in renal cell carcinoma and primary cell line cultures: Methodological implications for immunotherapy. Med. Sci. Monit. 15:638-645.
21. Iwaszko, M., and Bogunia-Kubik, K. 2011. Clinical signifcance of the HLA-E and CD94/NKG2 interaction. Arch. Immunol. Ter. Exp (Warsz) 59:352-367.
22. Kageshita, T., Hirai, S., Ono, T., Hicklin, D. J., and Ferrone, S. 1999. Down-regulation of HLA Class I antigen-processing molecules in malignant melanoma: Association with disease progression. Am. J. Pathol. 154:745-754. (Pubitemid 29122593)
23. Kageshita, T., Wang, Z., Calorini, L., Yoshii, A., Kimura, T., Ono, T., Gattoni-Celli, S., and Ferrone, S. 1993. Selective loss of human leukocyte Class I allospecifcities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of Class I human leukocyte antigens. Cancer Res. 53:3349-3354. (Pubitemid 23223308)
24. Kren, L., Slaby, O., Muckova, K., Lzicarova, E., Sova, M., Vybihal, V., Svoboda, T., Fadrus, P., Lakomy, R., Vanhara, P., Krenova, Z., Sterba, J., Smrcka, M., and Michalek, J. 2011. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: An unexpected prognostic signifcance? Neuropathology 31:129-134.
25. Levy, E. M., Bianchini, M., von Euw, E. M., Barrio, M. M., Bravo, A. I., Furman, D., Domenichini, E., Macagno, C., Pinsky, V., Zucchini, C., Valvassori, L., and Mordoh, J. 2008. Human leukocyte antigen-E protein is over-expressed in primary human colorectal cancer. Int. J. Oncol. 32:633-641. (Pubitemid 351330470)
26. Májský, A. 1989. Natural HLA-A, B and DR Abs in the serum of non-allo-immunized men. Vnitr. Lek. 35:467-471.
27. Malmberg, K. J., Levitsky, V., Norell, H., de Matos, C. T., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., and Kiessling, R. 2002. IFNγ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mecha-nism. J. Clin. Invest. 110:1515-1523. (Pubitemid 35396922)
28. Marin, R., Ruiz-Cabello, F., Pedrinaci, S., Mendez, R., Jimenez, P., Geraghty, D. E., and Garrido, F. 2003. Analysis of HLA-E expression in human tumors. Immunogenetics 54:767-775. (Pubitemid 36384471)
29. + cells. J. Neuroimmunol. 189:50-58. (Pubitemid 47379433)
30. Morales-Buenrostro, L. E., Terasaki, P. I., Marino-Vázquez, L. A., Lee, J. H., El-Awar N., and Alberú, J. 2008. "Natural" human leukocyte Ag Abs found in non-allo-immunized healthy males. Transplantation 86:1111-1115.
31. Nguyen, S., Beziat, V., Dhedin, N., Kuentz, M., Vernant, J. P., Debre, P., and Vieillard, V. 2009. HLA-E up-regulation on IFNγ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant. 43:693-699.
32. + T-lymphocytes in the adaptive immune response to pathogens and tumors. J. Biomed. Biotechnol. 2010 (907092):1-8.
33. Raine, T., Brown, D., Bowness, P., Hill-Gaston, J. S., Mofett, A., Trowsdale, J., and Allen, R. L. 2006. Consistent patterns of expression of HLA Class I free heavy chains in healthy individuals and raised expression in spondyloarthropathy patients point to physiological and pathological roles. Rheumatol. (Oxford) 45:1338-1344. (Pubitemid 44605466)
34. Ravindranath, M. H., Kaneku, H., El-Awar, N., Morales-Buenrostro, L. E., and Terasaki, P. I. 2010a. Antibodies to HLA-E in non-allo-immunized Males: Pattern of HLA-Ia-reactivity of anti-HLA-E-positive sera. J. Immunol. 185:1935-1948.
35. Ravindranath, M. H., Pham, T., El-Awar, N., Kaneku, H., and Terasaki, P. I. 2011a. Anti-HLA-E Monoclonal Ab 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C Alleles: Web-Tools validate the Immunogenic Epitopes of HLA-E recognized by the antibodies. Mol. Immunol. 48:423-430.
36. Ravindranath, M. H., Pham, T., Ozawa, M., and Terasaki, P. I. 2011b. Antibodies to HLA-E may account for the non-donor-specifc anti-HLA Class-Ia antibodies in renal and liver transplant recipients. Int. Immunol. (in Press, DOI: 10.1093/intimm/DXRO94).
37. Ravindranath, M. H., Taniguchi, M. C., Chen, W., Ozawa, M., Kaneku, H., El-Awar, N., Cai, J., and Terasaki, P. I. 2010b. HLA-E monoclonal Abs recognize shared peptide sequences on classical HLA Class Ia: Relevance to human natural HLA antibodies. Mol. Immunol. 47:1121-1131.
38. Riederer, I., Sievert, W., Eissner, G., Molls, M., and Multhof, G. 2010. Irradiation-induced up-regulation of HLA-E on macrovascular EC confers protection against killing by activated NK Cells. PLoS One 5:e15339.
39. Rodgers, J. R., and Cook, R. G. 2005. MHC Class Ib molecules bridge innate and acquired immunity. Nature Rev. Immunol. 5:459-471. (Pubitemid 40835034)
40. Seliger, B., Cabrera, T., Garrido, F., and Ferrone, S. 2002. HLA Class I antigen abnormalities and immune escape by malignant cells, Semin. Cancer Biol. 12:3-13. (Pubitemid 34087893)
41. Selvan, R. S., Pappas, T. N., and Ward, F. E. 2000. Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumor-reactive T-cells. Br. J. Cancer. 82:691-701. (Pubitemid 30085209)
42. Selvan, S. R., Carbonell, D. J., Fowler, A. W., Beatty, A. R., Ravindranath, M. H., and Dillman, R. O. 2010. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res. 20:280-292.
43. Selvan, S. R., Dillman, D. O., Fowler, A. W., Carbonell, D. J., and Ravindranath, M. H. 2008. Monitoring response to treatment in melanoma patients: Potential of a serum glycomic marker. Int. J. Cancer 122:1374-1383. (Pubitemid 351287239)
44. Strong, R. K., Holmes, M. A., Li, P., Braun, L., Lee, N., and Geraghty D. E. 2003. HLA-E Allelic Variants: Correlating diferential expression, peptide afnities, crystal structures and thermal stabilities. J. Biol. Chem. 278:5082-5090. (Pubitemid 36801018)
45. Tongio, M. M., Falkenrodt, A., Mitsuishi, Y., Urlacher, A., Bergerat, J. P., North, M. L., and Mayer, S. 1985. Natural HLA Abs. Tissue Antigens 26:271-285.
46. Ulbrecht, M., Couturier, A., Martinozzi, S., Pla, M., Srivastava, R., Peterson, P. A., and Weiss, E. H. 1999. Cell surface expression of HLA-E: Interaction with human β2-microglobulin and allelic diferences. Eur. J. Immunol. 29:537-547. (Pubitemid 29078514)
47. Zhou, B., Saito, S., Nakazawa, Y., Kobayashi, N., Matsuda, M., Matsumoto, Y., Hosoyama, T., and Koike, K. 2008. Existence of an immunoglobulin G component of naturally-occurring HLA Class I Abs that are not directed against self-Ags in human serum. Tissue Antigens 72:98-104. (Pubitemid 352009809)